Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants
RAS is the most frequently mutated oncogene in human cancer, yet limited treatments are available for patients with mutations beyond KRAS G12C. While pan-RAS inhibitors have entered the clinic to benefit a broader population of patients harboring RAS mutations, we sought to develop pan-KRAS inhibitors (selective for KRAS over HRAS and NRAS) that may offer an improved therapeutic index. Herein, we describe the discovery of GNE-6226, a pan-KRAS inhibitor exhibiting exquisite potency across a range of KRAS mutants. Using a structure-based design, we transitioned from mutant-selective inhibitors to a pan-KRAS inhibition profile, identifying the aminopyridine headgroup as a crucial motif. This headgroup establishes key ligand−protein interactions with conserved residues within the switch-II pocket while avoiding steric clashes with KRAS mutants. We present extensive cellular and in vivo profiling of GNE-6226, highlighting its robust MAPK pathway modulation and tumor growth inhibition in vivo across G12V- and G12D-mutant xenograft mouse models.
Authors
- Stephanie Dale
- Matthew L. Landry (ORCID: https://orcid.org/0000-0003-3202-2178)
- Elizabeth H. Kelley (ORCID: https://orcid.org/0000-0002-7005-6136)
- Luca Gerosa (ORCID: https://orcid.org/0000-0001-6805-9410)
- Marie Evangelista (ORCID: https://orcid.org/0000-0003-4623-1595)
- Jeremy M. Murray (ORCID: https://orcid.org/0000-0002-2161-9326)
- Cheng Shao
- Lionel Rougé (ORCID: https://orcid.org/0000-0002-7953-5803)
- Pablo Saenz-Lopez Larrocha (ORCID: https://orcid.org/0009-0002-3097-3156)
- Kamakoti P. Bhat (ORCID: https://orcid.org/0000-0001-7425-8336)
- Maureen H. Beresini
- Cecile C. de la Cruz
- 孙银蕾
- Darlene Dela Cruz
- Jack A. Terrett (ORCID: https://orcid.org/0000-0001-8777-046X)
- Jun Zou (ORCID: https://orcid.org/0000-0001-6036-8067)
- Binqing Q. Wei (ORCID: https://orcid.org/0000-0002-3654-3459)
- Lin Deng (ORCID: https://orcid.org/0000-0002-0132-1901)
- Mark A. Merchant (ORCID: https://orcid.org/0000-0003-0690-8581)
- Benjamin D. Ravetz
- F. Esra Demircioglu (ORCID: https://orcid.org/0000-0002-3866-2742)
- Thomas Hunsaker (ORCID: https://orcid.org/0000-0001-7665-747X)
- Matthew J. Saabye
- Sushant Malhotra
- Jingwei Cai (ORCID: https://orcid.org/0000-0002-3626-3350)
- Lewis J. Gazzard (ORCID: https://orcid.org/0000-0003-4448-2462)
- Aijun Lu
- Fang Ma
- Ehud Segal
- Stefan Chun
- Xin Ye
- Eva Lin
- Yulai Zhang
- Kaylee Lee (ORCID: https://orcid.org/0009-0007-3867-654X)
- Guosheng Wu
- Xiaodan Chang
- Weiru Wang
Institutions
- Genentech (US)
- Confluence Life Sciences (United States) (US)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c02035
- Primary Topic
- Protein Kinase Regulation and GTPase Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00